Would you consider a shorter course of Romosozumab (3 months) followed by maintenance therapy given recent evidence that it is noninferior to 12 months of therapy for treatment of severe osteoporosis?  

A recent publication led by Leder et al (Lancet Diabetes Endocrinol 2026;14: 216–22) demonstrated that a brief 3-month course of romosozumab followed by denosumab was noninferior to a full 12-month course of romosozumab given in the standard manner. This is consistent with earlier (nonrandomiz...

I read this study with interest. We knew early on that bone formation marker PINP went to baseline after 6-9 months. We also know from the large teriparatide study with fracture data that each additional month of anabolic therapy with PTH conferred an additional 30% reduction in fractures relative ...